Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Care management intervention strategies
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Care management intervention strategies

1 evidence topic · 1 source

Assessment at progression during TKI therapy

“Confirm adherence to treatment and rule out drug interactions at the time of progression to any TKI (III,B).” (opens the source at this quote in a new tab)